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Abstract 
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor 
system. Subunits of the 33-amino acid containing motorneurontrophic factor (MNTF) have been 
investigated and GM6 has been found as a potential peptide therapeutic for ALS. This linear peptide drug 
candidate has been characterized by HPLC based physicochemical and biomimetic measurements to 
estimate its in vivo distribution behavior and to estimate its cell penetration and brain to plasma 
concentration ratio. The free tissue concentration vs time profile has been estimated using the measured 
physicochemical and biomimetic properties of the intact GM6 molecules and its microsomal stability. The in 
vitro and in vivo measurements supported the estimated in vivo distribution behavior of GM6.  
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Introduction 
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human 
motor system. It is the most common motoneuron disease in human affecting approximately 2 people in 
100,000 in both the US and Europe and therefore it is considered as a rare orphan disease [1]. ALS 
manifests itself in the death of motoneurons which control the voluntary muscles. The cause of ALS is not 
known in 90 to 95 % of cases while familial inherited causes have been identified in 5 to 10 % of cases. 
There is no cure for ALS. The clinical onset of the disease usually starts at around age 60 and the survival 
time is around 2 to 4 years. It is very difficult to determine a specific date for the onset of the disease and 
the potentially long duration between the onset of pathological changes and the manifestation of the 
clinical disease. Patients can present with bulbar-onset disease (about 25 %) or limb-onset disease (about 
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70 %) or with initial trunk or respiratory involvement (5 %). Atypical modes of presentation can include 
weight loss, which is an indicator of a poor prognosis, cramps, emotional lability and frontal lobe-type 
cognitive dysfunction. 
The pathophysiological mechanisms underlying the development of ALS seem multifactorial with 
emerging evidence of a complex interaction between genetic and molecular pathways [2,3]. ALS is 
relentlessly progressive – 50 % of patients die within 30 months of symptom onset and about 20 % of 
patients survive between 5 - 10 years after symptom onset. Some ALS subtypes tend to lead to a better 
prognosis; for example, flail-limb variants ALS and progressive muscular atrophy. Both are predominantly 
lower motoneuron forms that are characterised by slower progression. Advances in the understanding of 
the glutamate neurotransmitter system and the discovery of causal genes linked to the development of 
familial ALS has stimulated research interest. The survival in ALS is now understood to be dependent on 
several factors, such as clinical presentation, the rate of disease progression, early presence of respiratory 
failure and the nutritional status of the patients. 
The process by which motoneurons die remains unclear with several inter-related mechanisms 
suggested [1]. The neurodegeneration in ALS may result from any of the following: complex interactions of 
glutamate excitotoxicity, generation of free radicals, cytoplasmic protein aggregates, SOD1 enzymes, 
combined with mitochondrial dysfunction, and disruption of axonal transport processes through the 
accumulation of neurofilament intracellular aggregates.  
Riluzole has been approved by the FDA for 20 years and inhibits the release of glutamic acid from 
cultured neurons, from brain slices, and from corticostriatal neurons in vivo. It increases the ALS patients’ 
life by two to three months by blocking glutamatergic neurotransmission in the CNS.  
There is an unmet medical need to lengthen the life expectancy, slow down the disease progression and 
ultimately cure ALS patients. Discovering a therapeutic agent that significantly increases the life expectancy 
of ALS patients or cures the disease would provide a significant breakthrough in this field.  
Potential disease mechanisms 
Protein misfolding and protein aggregation are known characteristics of various diseases, including 
major neurodegenerative disorders such as ALS, Alzheimer’s and Parkinson’s diseases. While the 
mechanistic link between protein aggregation and cell degeneration remains unclear, approaches to halt or 
reverse the aggregation process are a focus of current drug discovery approaches.  
Insulin-like growth factor-I (IGF-I) receptors are present in the spinal cord and, as members of the 
neurotrophin receptor family, IGF-I receptors mediate signal transduction via the tyrosine kinase domain. 
IGF-I was found to prevent the loss of choline acetyltransferase activity in embryonic spinal cord cultures, 
as well as reducing the programmed cell death of motor neurons in vivo during normal development or 
following axotomy [4]. Over the past 30 years, glucose intolerance has been reported in a significant 
percentage of ALS patients. A reduction in glucose receptor space and insulin resistance has been 
postulated for a number of neuromuscular diseases [5]. The structurally related peptides, insulin and 
insulin-like growth factors (IGF-I and IGF-II), have neurotrophic properties and potentially could be of 
therapeutic value in human neurodegenerative disorders [6]. 
The nerve growth factor (NGF) was discovered by Levi-Montalcini and Cohen some 50 years ago [7] 
which supported the concept that secreted molecules produced by the target of a developing neuron are 
required for it to survive programmed cell death (PCD). This neurotrophic hypothesis provided the 
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background for the identification of neurotrophic factors (NTFs). The motor neuron trophic factor (MNTF) 
is a 33-amino acid peptide. It was identified, isolated and characterized by using monoclonal antibodies 
against a 35 kD rat peptide, isolated from 3-week-old rat muscle extract. MNTF was subsequently derived 
by the cloning of a recombinant MNTF1-F6 gene from a human retinoblastoma cDNA expression library 
(Clontech) and analyzed to determine its amino acid and cDNA sequences [8]. GM6 is a 6 amino acid 
analogue of the MNTF active site. GM6 is a cationic linear peptide drug consisting of 6 amino acids in their 
natural configurations (Phe-Ser-Arg-Tyr-Ala-Arg acetate salt) [9,10]. MNTF 33 (1 µg/ml) and MNTF 10 
(1 µg/ml) induced differentiation of embryonic stem cells (ES) that resulted in the expression of the mature 
motor neuron transcription factors HB9, Chat and Islet 1/2. MNTF was found to have an affinity for the 
insulin receptor (IR) and the Insulin-like growth factor (IGF) of ES cells that resulted in the auto-
phosphorylation of Tyr972 and Tyr 1162/1163 markers of IR activation receptor (IGF-1R) based on 
embryonic stem cell differentiation studies [10].  
In this paper, the in vitro and in vivo properties of the MNTF-33 derived GM6, a six-amino acid part of 
the endogenous motor neuron trophic factor is described, summarizing its potential as a new peptide 
therapeutic for ALS. Peptide therapeutics have several advantages being highly selective and efficacious 
and are well tolerated with good safety profiles [11]. The challenges with peptide therapeutics are their 
impaired cell permeability and their stability in plasma that has to be improved [11]. Therefore, the 
biomimetic properties of GM6 have been measured by HPLC using chemically bonded protein and 
phospholipid stationary phases [12]. The models developed for small molecules [13] have been applied to 
estimate the in vivo PK profile of GM6 with special emphasis on the expected free tissue concentration. 
GM6 has been found to have good drug-like properties with an estimated good cellular accumulation and 
tissue partition as has been described previously [14]. 
Discovery of GM6 
GENERVON Biopharmaceuticals LLC has discovered and patented [9] several peptides. The hypothesis is 
that the master regulator for the differentiation of the human nervous system must be endogenous and 
the 3D structure should not be modified in order to be able to bind to a specific receptor. The natural 
motoneuron trophic factor (MNTF) consists of 33 amino acids. It's smaller analogue GM6 which is a partial 
sequence of MNTF and is a 6 amino acid cationic peptide. This potential drug modelled on an endogenous 
multi-target embryonic stage protein isolated from the nervous system. It was synthesized and then tested 
In the SOD1/G93A transgenic mouse model for ALS, GM6 delayed disease onset (27 %) and significantly 
extended the survival (30 %) and improved motor function (41- 43 %) [15]. 
Experimental  
Physicochemical and biomimetic property measurements – estimating in vivo distribution of GM6 
All high-performance liquid chromatography (HPLC) measurement were performed on an Agilent 100 
equipped with an ultraviolet diode array detector (UV-DAD). The reversed phase fast gradient retention 
times have been measured using a Gemini NT C-18 column with the dimensions of 50 x 3 mm, particle size 
5 µM with a 110 Å pore size (Phenomenex UK). 
The starting mobile phase was pH 2.6 0.01 M formic acid for low pH lipophilicity, 50 mM ammonium 
acetate buffers with pH adjusted to 7.4 and 10.5 by concentrated ammonia solution for neutral and basic 
pH lipophilicity measurements respectively. All reagents were HPLC grade obtained from 
Honeywell/Sigma-Aldrich, Germany. A 1.00 ml/min flow rate was applied. The acetonitrile gradient was 
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from 0 to 100 % from 0 to 3.5 min then 100 % acetonitrile was kept until 4.5 min and then returned to 0 % 
at 4.7 min. The run time was 6 min. HPLC grade water and acetonitrile were obtained from Rathburn 
Chemicals Ltd, Walkerburn, UK. The gradient retention times were standardized using the Valko test 
mixture and the chromatographic hydrophobicity index (CHI) values as described previously [13,16]. The 
CHI values were converted to the octanol/water log D scale using Equation 1. 
CHI log D = 0.0525 CHI – 1.467 (1) 
In this way, the peptides lipophilicity can be compared to their octanol/water lipophilicity. 
Measurements of membrane binding using immobilized artificial membrane (IAM) chromatography 
For the measurements of GM6 interactions with phospholipids, the gradient retention times have been 
measured using an IAM.PC.DD2 100x4.6 mm column with 10 µM diameter and 300 Å pore size particles. 
The starting mobile phase was 50 mM ammonium acetate with the pH adjusted to 7.4. The acetonitrile 
gradient was applied from 0 to 90 % from 0 to 4.75 min and kept at 90 % until 5.25 min. From 5.25 to 5.5 
min the acetonitrile concentration was dropped to 0 %. The mobile phase flow rate was 1.5 ml/min and 
the run time was 6 min. The retention times were standardized using the IAM calibration mixture as 
described previously [17] (Equation 2). 
log KIAM = 0.29*exp(0.046 CHI IAM+0.42) + 0.70 (2) 
The log KIAM values express the membrane partition comparable to the octanol/water lipophilicity. 
Protein binding measurements using biomimetic protein stationary phases 
The peptides interactions with human serum albumin (HSA) and alpha-1-acid-glycoprotein (AGP) have 
been measured using commercially available chemically bonded HSA (Chiralpak-HSA) and AGP (Chiralpak-
AGP) HPLC columns with the dimensions of 50 x 3 mm with a 5 µM particle size obtained from HiChrom 
Ltd, Reading, UK. The mobile phase was 50 mM ammonium acetate with the pH adjusted to 7.4. An iso-
propanol gradient (HPLC grade, Rathburn Chemicals, Walkerburn, Uk) was used from 0 to 35 % from 0 to 
3.5 min with a flow rate of 1.5 ml/min. The 35 % iso-propanol mobile phase was run till 4.5 min and then 
back to 0 % within 0.2 min. The run time was 6 min to allow re-equilibrate of the protein phase with the 
buffer. The retention times were standardized using the calibration set of compounds as described 
previously. Using the slope and intercept values from the calibration line the logarithmic retention times 
were converted to log k values that can be converted to % binding values (% HSA and % AGP) using 












In order to be able to estimate the in vivo distribution, cell penetration, cell membrane affinity and 
plasma protein binding biomimetic HPLC characterization of GM6 were carried out using the methods 
described earlier [13,14,19]. The in vivo distribution behaviour of GM6 has been estimated on C-18, IAM, 
HSA and AGP stationary phases based on the measured generic gradient retention times described above. 
The model equations with the source references are listed in Table 1. 
Stability measurements in human plasma 
The plasma stability of GM6 has been investigated by using a standard HPLC/MS/MS procedure by 
Frontage Laboratory Inc (Malvern, PA, USA). This bioanalytical laboratory measured the concentration of 
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GM6 in human plasma using K2EDTA as the anticoagulant. The system was calibrated using GM6 in the 
concentration range of 250 ng/ml to 50 mg/ml. The mean GM6 concentration was measured at 10, 15, 30 
and 60 min time points after incubation. A considerable difference was observed in the mean 
concentration of the peptide GM6 within each individual lot of whole human blood at times 10, 15, 30 and 
60 min compared with the 1 minute time point, which indicated that in the absence of stabilizer, GM6 is 
not stable in fresh human blood. It is worth mentioning that in this study only the intact GM6 molecule 
concentration was monitored.  
Table 1. The model equations used to derive estimated in vivo distribution (log Vdss = 
logarithm of the volume of distribution, log Vdu= logarithm of the unbound volume of 
distribution), drug efficiency (DEmax), brain tissue binding (log kBTB), fraction unbound in brain 
and plasma (fuBTB and fuPPB), brain to plasma ratio (kbb) and cell partition log Kpcell). 
log KIAM [17] = 0.29*e
(0.026CHI(IAM)+0.42
) + 0.7 
Log kIAM [17] =0.046*CHI(IAM) + 0.42 
log KHSA [17] = e
log k(HSA) 
 
log kHSA [18] = log (%HSAbound/(101- %HSA bound))  
Estimated log Vdss [17] = 0.44*log KIAM -0.22*log KHSA - 0.62  
Estimated log Vdu [20] = 0.23*log KHSA +0.43*log KIAM - 0.72  
DEmax [21] = 100/Vdu  
log kBTB [22] =1.29*log kIAM+1.03*log kHSA - 2.37 
log kPPB [22] =0.98∗log 𝑘𝐻𝑆𝐴+0.19∗log 𝑘𝐴𝐺𝑃+0.031∗CHI log D7.4−0.20  
%BTB [22] =100*10
 log kBTB /(1+10
 log kBTB) 
%PPB [22] =100*10
log kPPB/(1+10
 log kPPB) 
fu BTB and PPB [22] =(100-%BTB)/100 and (100-%PPB)/100 
Kbb [22] = fuPPB/fuBTB 
log Kpcell [23] =1.1*log kIAM - 1.9 
In vitro clearance and estimated PK profile of GM6 
In order to estimate the expected PK profile of GM6 in human the in vitro microsomal stability has been 
measured. Eurofins Pharma Discovery Services Cerep Inc (France) carried out in vitro clearance 
measurements on GM6 using human liver microsomes. The in vitro clearance data so obtained can be used 
to estimate the in vivo clearance and half-life using a well-stirred model [24]. A comparative study was 
carried out using GM6 and Riluzole, an FDA approved drug for ALS. The purpose of the study was to test 
whether there was any interaction between GM6 and Riluzole in the intrinsic clearance assay using human 
liver microsomes.  
A pool of 50 mixed gender human liver microsomes was used with a final microsomal concentration 0.1 
mg/ml. The test compounds were dissolved to a 0.1 µM concentration in 0.01% DMSO, 0.25 % acetonitrile 
and 0.25 % methanol. The test compounds were pre-incubated with the pooled liver microsomes in 
phosphate buffer and shaken for 5 min at 37 centigrade. The reaction was initiated by an NADPH-
generating system and incubated for 0, 15, 30, 45 and 60 min. The reaction was then stopped by 
transferring the incubation mixture to an acetonitrile/methanol mixture. Samples were then mixed and 
centrifuged and the supernatant analysed by HPLC-MS/MS. The compound remaining after incubation was 
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calculated from the peak area obtained for each sample time point relative to the zero-time point. The 
half-life was calculated from the slope of the initial linear range of the logarithmic curve of the compound 












Quantitative immunofluorescence imaging  
Phenovista Biosciences LLC (San Diego, CA, USA) provided several phenotypic assays on four different 
cell types treated with GM6 in order to reveal the presence of, and reaction to, GM6 in these cells. The 
primary goal of the study was to identify antibody-based markers that could be used successfully in 
quantitative imaging-based analysis and to determine if the application of GM6 caused quantifiable effects 
on signalling pathways identified by a series of antibody markers. Four human cell types were used:  
1. iPS-derived iCell hepatocytes 2.0 (CDI PHC-100-020-001) (cultured 10 days in manufacturers 
suggested media then treated with GM6), 
2. human brain microvascular endothelial cells [HBMVECs] (iX Cells 10HU-051) (cultured 2 days in 
manufacturers suggested media then treated with GM6), 
3. ntera2 differentiated cells (ATCC #CRL-1973) (differentiated for 21 days in 10 µM retinoic acid (RA), 
0.5 mM IBMX and 1 mM 8-Br-cAMP then treated with GM6), 
4.  iPS-derived iCell GABAergic neurons (CDI NRC-100-010-001) (cultured 7 days in manufacturers 
suggested media then treated with GM6). 
All cells were cultured and treated in high density 384 well microplates before fixation, 
immunofluorescence staining and analysis using automated quantitative microscopy. The aim of the 
analysis was to determine uptake and downstream signalling effects of GM6 via assessment of the marker 
levels in each cell type under each treatment condition. Due to the unknown distribution and response of 
the twelve unique markers selected, a general-purpose image analysis strategy was taken whereby 
changes in cellular intensity for each marker would be quantified. 
Cells were seeded in 384 well plates (Greiner) in culture media according to manufacturer’s guidelines 
and where applicable differentiated before treatment with GM6 for 15 minutes, 2 or 4 hours. Treatments 
were performed via the addition of a 10x solution as 10 % of the final culture volume (e.g. 2.2 µl of 10 mM 
GM6 added to 20 µl culture volume for a final concentration of 1 mM GM6). After treatment the cells were 
fixed in 4 % formaldehyde for 15 minutes, washed in PBS containing 0.3 % Triton X-100 for 5 minutes at 
room temperature then blocked in PBS containing either 5 % goat serum or 5 % donkey serum (depending 
on primary antibody host used), 1 % BSA, and 0.2 % fish gelatin overnight at 4 °C. Primary antibody diluted 
in blocking buffer was incubated at 4 °C overnight followed by three washes in PBS then fluorescently-
conjugated secondary antibodies (1:500 dilution, and Hoechst 33342 (10 µg/ml final) added in PBS and 
incubated at room temperature for 1 hour before washing in PBS three times and storage at 4 °C.  
Twelve unique markers were assessed in combination with the nuclear marker Hoechst 33342 in six 
staining sets (aka palettes); chicken anti-GM6 (Genervon), rabbit anti-insulin receptor (Abcam #ab131238), 
goat anti-SOD1 (Abcam #ab62800), mouse anti-insulin receptor beta (Abcam #ab983), rabbit anti-phospho 
Tau S356 (Abcam #ab75603), mouse anti-PI3Kp85 (Abcam #ab86714), rabbit anti-TDP43 (ThermoScientific 
#PA5-29949), rabbit anti IGF1 receptor beta (Cell Signalling #9750), mouse anti-tau (Synaptic Systems 
Klara Valko et al.  ADMET & DMPK 6(2) (2018) 176-189 
182  
#314011), rabbit anti-phospho tau T231 (Abcam #ab151559), mouse anti-IGF1 receptor (Abcam ab16890) 
and rabbit anti-phospho insulin recptor beta Y972 (Abcam 5678).  
Imaging was performed using a ThermoScientific CX7 automated fluorescence microscope. Images were 
collected using filter sets appropriate for the fluorescently-conjugated secondary antibodies and images 
analysed using the Compartmental Analysis (ThermoScientific) algorithm as part of the HCS studio software 
package. Data were processed using Microsoft Excel to calculate mean, standard deviation and strictly 
standardized mean difference (SSMD) scores to assess statistical significance versus control treatments. 
In vivo brain penetration studies 
C57BL6 mice were injected with a single bolus IV tail vein injection of GM6 at 0.2 and 2.0 mg/kg. At four 
hours, the animals were sacrificed, and half of the brain was frozen for ELISA analysis. The detailed 
experimental process has been published previously [25]. 
Results and Discussion 
Physicochemical and biomimetic properties of GM6 
It is important to determine how GM6 behaves in vivo and what are its physicochemical and drug-like 
properties and can it’s in vivo distribution and pharmacokinetic behaviour be predicted. Similar to other 
peptide therapeutics it was expected that GM6 would not be stable in plasma, so measurement of the 
traditionally used plasma vs. time PK profile would not be feasible. Therefore, the protein and phospholipid 
binding of GM6 was assessed using biomimetic HPLC experiments. The results of the measurements of 
protein and phospholipid binding of GM6 are listed in Table 2, including the estimated in vivo distribution 
properties of GM6 using the model equations listed in Table 1. 
It can be seen that due to the two arginine amino acids in the sequence GM6 is positively charged at 
physiological pH. Therefore, it's binding to alpha-1-acid glycoprotein (AGP) and Immobilized Artificial 
Membrane (IAM) is very strong. The total plasma protein binding is expected to be 31%. However, due to 
the strong IAM binding, it is very likely that GM6 also partitions quickly into the blood cells. The volume of 
distribution was estimated from the difference of binding of GM6 to albumin and IAM according to the 
model published for marketed drugs [17] that was 7.8 L/kg using the equation listed in Table 1. 
The brain tissue binding of GM6 is estimated to be 58.3% which is higher than the plasma protein 
binding suggesting higher total brain concentration than total plasma concentration. The brain to plasma 
total concentration ratio is expected to be 1.65. Due to the strong IAM binding, the estimated intracellular 
concentration is approximately 5 times higher than the extracellular concentration using the models 
obtained with HELA cell [23]. The drug efficiency which is defined as the free bio-phase concentration 
relative to the dose [26] is over 8% which is much above the expected 1% that is characteristic of the 
marketed drugs. 
From the biomimetic models only, the total brain to plasma concentration ratio can be estimated based 
on the difference between the brain tissue and the plasma protein binding as shown in Table 1.  
Figures 1 and 2 show that GM6 has good drug-like properties similar to marketed small molecule drugs. 
GM6 is well positioned in the middle of the marketed drugs based on the plot of the estimated brain to 
blood ratio (log kBB) and steady-state volume of distribution (log Vdss). 
It was found that 70 % of GM6 was stable in human liver microsomes after 60 min. The addition of 
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Riluzole to the liver microsomes did not change the clearance of GM6 nor the Riluzole clearance, 
suggesting no drug-drug interactions. Further studies will be needed to estimate the renal clearance of 
peptides which is a more typical route of elimination [27]. 
Table 2. The measured biomimetic properties of GM6 using published models for small molecule 
marketed drugs [22] 
Property Value Explanation 
% bound HSA 22.90 Albumin binding 
% bound AGP 45.06 Glycoprotein binding 
Calc % PPB 31.40 Plasma protein binding 
Calc % Blood 23.60 Blood binding 
CHI log D2 -3.38 Lipophilicity at pH 2 
CHI log D7.4 -0.16 Lipophilicity at pH 7.4 
CHI log D10.5 0.20 Lipophilicity at pH 10.6 
CHI log P 0.20 Neutral form lipophilicity 
IAM 42.5 Phospholipid binding 
CAD-likeness 49.4 Phospholipidotic potential 
est log BB 0.22 Brain to blood ratio (log) 
Brain to plasma 1.65 Brain to plasma ratio 
log Vd 0.89 log Volume of distribution 
Vd L/kg 7.83 Volume of distribution 
log Vdu 1.06 log Unbound volume of distribution 
Vdu 11.5 The unbound volume of distribution 
DEmax% 8.74 max Drug efficiency 
MW 799.00 Molecular weight 
log kBrain 0.15 Brain tissue partition 
% BTB 58.3 Brain tissue binding 
log k lung tissue 0.51 Lung tissue partition 
% lung tissue binding 72.3 Lung tissue binding 
log Kp skin -7.10 log Skin partition 
log Kp skin -7.69 Skin partition 
log Kp cell 0.71 log cell partition 
Kp cell 5.2 Cell partition 
It is well-known that plasma proteases can hydrolyse peptides rapidly and that special method should 
be applied to the plasma concentration determination [28,29]. GM6 showed 15 min half-life in vitro in 
human blood. 
It has been also reported that some therapeutic peptides could not be detected in the plasma but they 
still had a long-lasting pharmacological effect [30]. There are various methods for increasing the plasma 
half-life of peptides such as replacing L-amino acids to D- amino acids, blocking the N or C terminals, 
conjugations to macromolecules like PEG and cyclisation [27]. Other approaches such as increasing the 
albumin binding are also used to improve the physicochemical and in vivo ADMET properties of peptides 
[31] in order to open up new modalities in drug discovery. With GM6, the idea was not to change the 
peptide structure but to remain close to the endogenous MNTF using the 6-amino acid sequence which 
was thought to be responsible for the neuroprotective effect.  
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Figure 1. Boxplot of the average estimated log kBB values of marketed drugs, drugs that enter into the central 
nervous system (CNS) and inhaled drugs, as well as GM6. The estimated brain to plasma total concentration 
ratio was calculated using the equations given in Table 1.  
 
Figure 2. The plot of the estimated brain to blood ratio (log kBB) and the steady-state volume of distribution 
(log Vdss) of marketed drugs that enter into the CNS. 
Based on the measured physicochemical and biomimetic properties listed in Table 2, it can be seen that 
GM6 is predicted to have high cell partition (Kpcell = 5.2) which means 5 times higher concentration inside 
the cells that outside the cells. The model has been developed using 300 compounds data that were 
equilibrated with HELA cells and measured the intracellular concentration [23]. HELA cells do not contain 
active transporters, so it can be assumed that this is the passive partition of GM6 into cells. 
Quantitative immunofluorescence imaging  
The results of the quantitative imaging experiments gave a very good indication that GM6 associates 
with cells well, especially to iPS-derived neurons. GM6 demonstrated quantifiable labelling of cellular 
structures in all of the cell types tested with chicken anti-GM6 (Genervon). While it is difficult to determine 
whether GM6 was restricted to the surface of the cells that it interacted with or was internalized or 
degraded, based on the time and dose-dependent effects on markers, it did suggest that GM6 was able to 
elicit cellular responses that could be a result of cell surface binding, via uptake or via a combination of 
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both processes. It was found that an increase in GM6 abundance in all cell types could be quantified. The 
response of GM6 treatment on the GABAergic neurons was much more significant than on the 
hepatocytes, which suggested a specific affinity of GM6 to tissues of the nervous system and less so to the 
liver. Based on the study we can hypothesize that this cationic peptide, GM6, crosses the cell membrane 
and enters the cytoplasm. Figure 3 shows representative immunofluorescence images obtained in GABA 
neuron cells after treatment of GM6. 
 
 
Figure 3. Immunofluorescence images obtained after treating the GABA neuron cells with 1 mM GM6 or PBS-
only control. (Top row shows staining of human iPS-derived GABAergic neurons treated with 1 mM GM6 for 
15 minutes while the bottom row shows control PBS-treated neurons. Leftmost panels show Hoechst staining 
that identifies neuronal nuclei. Panels in the middle column show detection of GM6 in the same cells using an 
anti-GM6 antibody while columns to the right show corresponding insulin receptor staining intensity, which 
has been included to show the location of the cell bodies and neurites. Red arrows show GM6 in the cell body 
while yellow arrows show GM6 puncta localized to neurites. In some cases, staining of GM6 and InsR is 
coincident.) 
Results of the in vivo brain penetration studies in mice 
ELISA assays with brain homogenate supernatant detected GM6 at statistically significant levels, at all 
doses, compared to the control (p=0.0001) as shown in Figure 4. The vehicle group has some detection of 
GM6 (0.4050 µM). The 0.2 mg/kg group has 1.76 µM, the 2.0 mg/kg group has 12.92 µM. If we subtract the 
GM6 in the vehicle group, the net increase from injection of GM6 for the 0.2 mg/kg is 1.36 µM, for the 2.0 
mg/kg is 12.52 µM. The net increase of GM6 detected is almost proportional. 
These results support the prediction that GM6 can partition into tissues based on its large volume of 
distribution and that has also a good brain penetration [25] (brain to plasma ratio was estimated as 1.65 as 
indicated in Table 2).  
Estimated PK profile of GM6 
In order to estimate the dose we have calculated the minimum effective concentration of GM6 
obtained from the in vivo mouse experiment described in more detail later. The in vivo results showed that 
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a 20 mg/kg dose of GM6 was efficacious in the mouse. Using the 12.3 factor from mouse to human 
according to the FDA guidelines [32], the dose was estimated to be 1.6 mg/kg in human. As the drug 
efficiency of the compound is around 8 % it means that only 8 % of the administered dose is available as 
free. That is equivalent to 0.08·1.6 mg/kg, which is 0.13 mg/kg which equals 1.3·10
-4 
g/kg. Taking into 
account the 799 Da molecular weight of GM6 it is equivalent to a 1.6·10
-7
M concentration. It means that 
the pIC50 or in other words the minimum effective concentration (MEC) of the peptide is estimated to be 
around 1.6·10
-7 
M. The dose can be estimated from the pIC50 and the drug efficiency as it has been 
described earlier [21]. This dose estimation refers to a steady state and does not take into account the 
elimination rate and dosing frequency. 
 
Figure 4. Detection GM6 in mouse brain after four hours of the treatment by ELISA analysis. 
Using the one-compartment model [33] and a 132.5 mg dose for an average 70 kg human, a 










  (5) 
Where τ is the dosing interval, kel is the elimination rate calculated from the in vitro clearance (Equation 
(4)), Vdss is the steady-state volume of distribution, F is the bioavailability considered 1 and the absorption 
rate considered fast after IV administration.  
The intrinsic clearance (Clint) for GM6 in human microsome assays was determined to be < 115.5 
µg/mL/min/mg. To convert the Clint data from 115 ug/min/mg human liver microsomes to mL/min/kg we 
used the human scaling factor of mg protein in liver: 115 x 39.7 = 4565.5 µg/min/g liver which is equivalent 
to 4565/1000 = 4.565 ml/min/g liver. This value should go to the well-stirred model (WSM) to estimate the 
human whole-body clearance (kel). Using the WSM model it is equivalent to 15.5 ml/min/kg (which is 
equivalent to 86 % of the liver blood flow) as the clearance of GM6 which is relatively rapid. It is supposed 
that GM6 being an endogenous neuropeptide with two positive charges and relatively small (MW=799) the 
liver microsomes provide the major elimination route. It is also important to note that GM6 has a large 
estimated volume of distribution (over 7.8 L/kg) unlike other peptides and it binds to phospholipid very 
strongly (CHI IAM value is above 42). In a recent review [34] about the pharmacokinetic studies of protein, 
drugs raise the question whether the blood concentration is relevant or not to pharmacodynamics with the 
emphasis on the tissue concentration.  
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Table 3. The parameters used in estimating the PK profile of GM6 in human after 132 
mg iv dose. 
Body Weight (kg) 70 
Dosing interval (τ) 1 
Dose (mg/day) 132.5 
Dose (mg/Kg) 1.89 
Vd (L/Kg) 7.8 
CL (mL/min/Kg) 15.5 
CL (L/h/Kg)) 0.93 
CL (mL/min) 1085.0 
CL/F (mL/min) 1085.0 
CL/F (L/min) 1.085 
fu blood (%) 68.60 
Tmax (h) 0.8 
Cmax (ng/mL) 222 
Ke (1/h) 0.12 
t1/2 (h) 5.8 
AUC (ng/ml*h) 2037 
Vdu (L/Kg) 11.4 
DRUGeff MAX (%) 8.8 
DRUGeff Blood Cmax u  (%) 8.03 
Compound Information GM6 
Molecular weight 799 
pXC50 (based on in vivo efficacious concentration) 7 
Conc (nM) 100.00 
Total Conc (nM) 145.77 
Conc (ng/mL) 79.90 
Total Conc (ng/mL) 116.47 
Equation 5 describes the hypothetical plasma concentration vs time profile of drugs. As GM6 has a short 
half-life in plasma but it was detected in brain tissue after 4 hours, instead of the total plasma 
concentration vs time profile the free concentration-time profile was calculated that is referred to tissues. 
The estimated half-life in tissues including only the microsomal clearance was calculated as 5.8 h. 
This PK profile would have been very difficult to measure in vivo due to the technical difficulties of 
detecting GM6 in human blood. At this stage, the renal clearance of the compound had not been tested. 
Even if the elimination rate is double (30 ml/min/kg) due to renal clearance of GM6 we can expect 3 hours 
half-life in the tissues when calculated using equation 5. 
Conclusions 
In this paper, results have been shown and discussed for a 6-amino acid fragment (GM6) of the 
endogenous motor neuron trophic factor (MNTF) containing 33 amino acids and further discussed as a 
potential peptide therapeutic for amyotrophic lateral sclerosis (ALS). The physicochemical properties of 
GM6 were measured using biomimetic HPLC membrane and protein binding. GM6 showed very good drug-
like properties. Due to the two positively charged arginine amino acids and based on the measured 
phospholipid and protein binding, GM6 has been predicted to have very strong tissue partition with an 
estimated volume of distribution of 7.8 L/kg. It was also predicted that it partitions into cells (Kpcell = 5.2) 
and has a good brain to plasma ratio (1.65). Studies in mice show penetration of the GM6 into the brain 
following a bolus iv injection with the drug still present after four hours. The concentration of GM6 
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decreased rapidly in blood suggesting a high affinity for target sites in the brain and/or active uptake into 
brain cells and GABA-ergic neuron cells as shown by immunofluorescence imaging studies. The estimated 
free tissue concentration – time profile based on only microsomal elimination showed approximately 6 
hours half-life. The in vivo beneficial effects of GM6 are longer lasting. This would indicate that it probably 
provokes a cascade of biochemical events, after initial binding, and that influences multiple pathways that 
promote neuron regeneration. 
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